Table 2.
Summary of outcome in SHARP and Asia-Pacific studies
| Efficacy parameter | SHARP
|
Asia-Pacific
|
||||
|---|---|---|---|---|---|---|
| Sorafenib (n = 299) |
Placebo (n = 303) |
HR | Sorafenib (n = 150) |
Placebo (n = 76) |
HR | |
| OS (months) | 10.7 | 7.9 | 0.69 (P < 0.001) |
6.5 | 4.2 | 0.68 (P = 0.014) |
| TTP (months) | 5.5 | 2.8 | 0.58 (P < 0.001) |
2.8 | 1.4 | 0.57 (P < 0.001) |
| TTSP (months) | 4.1 | 4.9 | 1.08 (P = 0.768) |
3.5 | 3.4 | 0.90 (P = 0.498) |
| DCR (%) | 43 | 32 | (P = 0.002) | 35.3 | 15.8 | (P = 0.0019) |
Abbreviations: HR, hazard ratio (sorafenib versus placebo); OS, overall survival; TTP, time to progression; TTSP, time to symptomatic progression; DCR, disease control rate.